BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Andreas Argyrides does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 SPRYARS Pharmaceuticals, Inc | Buy | $19.00 | Mar 2024 | +35.4% | Miss |
 RANIRani Therapeutics Holdings Inc | Buy | $8.00 | Feb 2024 | −66.5% | Hit |
 OCSOculis Holding AG Ordinary shares | Buy | $29.00 | Nov 2023 | +40.4% | Miss |
| SPRYARS Pharmaceuticals, Inc | Buy | $13.00 | Nov 2023 | +275.7% | Hit |
| SPRYARS Pharmaceuticals, Inc | Buy | $5.00 | Sep 2023 | +252.2% | Hit |
| RANIRani Therapeutics Holdings Inc | Buy | $20.00 | Aug 2023 | −48.3% | Miss |
| SPRYARS Pharmaceuticals, Inc | Buy | $15.00 | Jun 2023 | +8.5% | Miss |
| SPRYARS Pharmaceuticals, Inc | Buy | $17.00 | May 2023 | −7.9% | Miss |
| SPRYARS Pharmaceuticals, Inc | Buy | $17.00 | May 2023 | +3.3% | Miss |
| SPRYARS Pharmaceuticals, Inc | Buy | $17.00 | May 2023 | +84.7% | Miss |
| OCSOculis Holding AG Ordinary shares | Buy | $27.00 | Apr 2023 | −5.4% | Miss |
| SPRYARS Pharmaceuticals, Inc | Buy | $10.00 | Jan 2023 | −17.2% | Miss |
 IMUXImmunic Inc | Buy | $5.00 | Jan 2023 | −59.3% | Miss |
 PCRXPacira BioSciences, Inc. | Buy | $60.00 | Jan 2023 | −26.2% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.